Healthcare Providers

How You Can Help

There are options available for your patients with EGFR-Positive Non-Small-Cell Lung Cancer (NSCLC)

Biomarker testing in your NSCLC patients is an important first step toward determining whether they could be eligible to participate in clinical research studies evaluating investigational medications for the treatment of NSCLC.

Advances in Treatment

Tremendous advances have been made in the treatment of NSCLC that is positive for epidermal growth factor receptor (EGFR) mutations.1From 2003-2016, nearly half of the new medications approved for the treatment of lung cancer addressed this particular molecular profile.1

Despite this progress, there is still a need for investigational medications that aim to target EGFR mutations, as some lung cancers with EGFR mutations don’t respond to current targeted medications, and those that do almost always become resistant over time.

Investigational medications are currently
being studied for adults with NSCLC.

The following research studies are currently evaluating the safety and efficacy
of investigational medicines for the treatment of NSCLC in patients with EGFR.

The PAPILLON Study for adults with advanced or metastatic NSCLC that has EGFR Exon 20
insertion mutations.
Download the HCP PAPILLON Study Guide.
The MARIPOSA Study for adults with newly diagnosed locally advanced or metastatic NSCLC with EGFR Exon 19 deletion or Exon 21 L858R substitution.
Download the HCP MARIPOSA Study Guide.
Next Generation Sequencing (NGS) over Standard Biomarker Testing

NGS is a DNA sequencing technology method that can detect abnormalities across the entire genome, including substitutions, deletions and insertions. Using NGS, multiple genes can be tested for mutations simultaneously, often in less time and at less cost than standard sequencing approaches.2

The more we learn, the farther we can go.

If you have an EGFR-positive patient that may be a candidate for one of these clinical research studies, or would like to share this information with a colleague, you can do any of the following:

Share & Educate

Share this website to provide education and awareness about these investigational research studies. Patients can also take a simple questionnaire to see if they may be eligible.

Share This
Encourage Contact

Encourage your patient to contact our nurses to ask any questions they may have and see if they may be eligible to participate in a study.

Call 1800 860 819
Download & Share

Download and share a patient brochure with more information on the Papillon Study.

Visit Global Trial Finder to locate Janssen clinical research studies that may be looking for participants all around the world.

If you have EGFR-Positive Non-Small-Cell Lung Cancer, your journey may include a different path. 

The more we learn, the farther we can go.

See If You Are Eligible